In part two of this series, Drs. Shuvro Roy, Jiwon Oh, and Amit Bar-Or discuss the results of the FENhance 1 and 2 trials looking at fenebrutinib in relapsing  MS. 

For more information, please read about the abstract that was presented at the 2026 AAN Annual Meeting. 

Read more about the Fenebrutinib Trial.